Proactive Investors
13 Oct 2026, 09:41 UTC · 1h ago
Impact · against what's priced in
The news is largely non-catalytic for GSK as the predicted Q3 headwinds in vaccines and tailwinds in HIV/Respiratory are well-known trade-offs. Arecor Therapeutics shows mild positive momentum from development progress on insulin and GLP-1 treatments, though this remains early-stage.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish · 0 new · 4 priced in
A US regulatory decision on hepatitis B treatment bepirovirsen is due on 26 October.
Priced inbroker note analysis
So whatThis binary event occurs just two days before the Q3 earnings call on October 28.
More positive than 93% of claims this week
RBC forecasts Q3 revenue of £8.82 billion, approximately 1% below the consensus estimate of £8.89 billion.
Continue reading
5 related stories
The CEO reported development progress on ultra-rapid-acting insulins and oral GLP-1 receptor treatments, providing a positive update on the company's clinical pipeline.
Read from the article alone
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Priced inbroker note analysis
So whatA miss on the top line may put pressure on the multiple despite the expected 50.8p core EPS.
More negative than 78% of claims this week
RBC forecasts Shingrix Q3 sales of £800 million, missing the consensus estimate of £837 million.
Priced inbroker note analysis
So whatThis £37 million shortfall is driven by high channel inventories in China and slowing European growth.
More negative than 70% of claims this week
RBC forecasts Nucala Q3 revenue of £623 million, which is roughly 7% above consensus.
Priced inbroker note analysis
More positive than 54% of claims this week
Which stocks this story touches
More positive than 57% of ticker scores this week
The CEO reported progress in the development of ultra-rapid-acting insulins and oral GLP-1 receptor treatments.
More positive than 51% of ticker scores this week
RBC Capital Markets expects broadly in-line results with strength in HIV and respiratory drugs offsetting weaker vaccine sales.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Reuters
2h ago
—
AREC hasn't traded since this ran. Last close $1.50 (Oct 12); the reaction starts at the next open.
AREC chart →
